Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs.
Previous reports have shown that interleukin-6 (IL-6) enhances the responsiveness of platelets to thrombin stimulation and has modest thrombocytopoietic effects in vivo. Thrombopoietin (TPO; mpl ligand) has been shown to have dramatic thrombocytopoietic effect in vivo, but little is known of its capacity to alter platelet function. In this study, a direct comparison of the effects of IL-6 and TPO on platelet function in dogs has been performed, with modest doses of TPO (1 microgram/kg/d) chosen to match or moderately exceed the platelet counts achieved with IL-6 (40 micrograms/kg/d) for 10 days. Platelet responsiveness to thrombin stimulation was assessed in TPO-treated, IL-6-treated, and control dogs by flow cytometric measurement of P-selectin expression. On day 5, the dose of thrombin promoting half maximal stimulation (EC50) of platelets was not significantly changed in TPO-treated dogs, whereas in IL-6-treated dogs the EC50 decreased to 73.1% +/- 6.1% (mean +/- 1 SD; n = 5) of control values (P < 0.01). These experiments were performed on both gel-filtered platelets and washed whole blood, indicating that the observed changes in EC50 were caused by cytokine-mediated alteration of platelets rather than plasma components. Because it has been shown that thiazole orange specifically labels a subpopulation of dog platelets that is less than 24 hours old, the thrombin responsiveness of these young, newly synthesized platelets was determined. The EC50 of thiazole orange-positive platelets from IL-6-treated dogs decreased dramatically by day 5 to 46.5% +/- 13.1% (n = 4) of control values (P < 0.001), whereas TPO-treated dogs did not significantly change. When TPO was directly incubated with platelets ex vivo, no effects on either thrombin-mediated P-selectin expression or adenosine diphosphate-induced fibrinogen binding were observed. These data show that IL-6 alters platelet function, as measured by reactivity to thrombin, whereas TPO does not. This divergence in function is observed even though TPO is equally, or more, effective at promoting platelet production under these experimental conditions.
Peng
J
J
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA.
Friese
P
P
Wolf
R F
RF
Harrison
P
P
Downs
T
T
Lok
S
S
Dale
G L
GL
Burstein
S A
SA
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D052160:Benzothiazoles; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D004396:Coloring Agents; D004285:Dogs; D005340:Fibrinogen / Q000378:metabolism; D005434:Flow Cytometry; D006410:Hematopoiesis / Q000187:drug effects; D015850:Interleukin-6 / Q000494:pharmacology*; D008533:Megakaryocytes / Q000166:cytology / Q000187:drug effects; D019007:P-Selectin / Q000096:biosynthesis; D015539:Platelet Activation / Q000187:drug effects; D011804:Quinolines; D011994:Recombinant Proteins / Q000494:pharmacology; D013844:Thiazoles; D013917:Thrombin / Q000494:pharmacology; D013926:Thrombopoietin / Q000494:pharmacology*
D052160:Benzothiazoles; D004396:Coloring Agents; D015850:Interleukin-6; D019007:P-Selectin; D011804:Quinolines; D011994:Recombinant Proteins; D013844:Thiazoles; C051000:thiazole orange; D000244:Adenosine Diphosphate; D005340:Fibrinogen; D013926:Thrombopoietin; D013917:Thrombin